ATE519780T1 - Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen - Google Patents

Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen

Info

Publication number
ATE519780T1
ATE519780T1 AT06841562T AT06841562T ATE519780T1 AT E519780 T1 ATE519780 T1 AT E519780T1 AT 06841562 T AT06841562 T AT 06841562T AT 06841562 T AT06841562 T AT 06841562T AT E519780 T1 ATE519780 T1 AT E519780T1
Authority
AT
Austria
Prior art keywords
compositions
insulin
zinc
producing
acylated insulin
Prior art date
Application number
AT06841562T
Other languages
German (de)
English (en)
Inventor
Svend Havelund
Frantisek Hubalek
Helle Olsen
Ib Jonassen
Thomas Hoeg-Jensen
Anne Plum
Ulla Ribel-Madsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36888823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE519780(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE519780T1 publication Critical patent/ATE519780T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06841562T 2005-12-28 2006-12-21 Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen ATE519780T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05113021 2005-12-28
PCT/EP2006/070104 WO2007074133A2 (en) 2005-12-28 2006-12-21 Compositions comprising an acylated insulin and zinc and method of making the said compositions

Publications (1)

Publication Number Publication Date
ATE519780T1 true ATE519780T1 (de) 2011-08-15

Family

ID=36888823

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06841562T ATE519780T1 (de) 2005-12-28 2006-12-21 Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen

Country Status (10)

Country Link
US (2) US20090074882A1 (https=)
EP (2) EP2505593A1 (https=)
JP (3) JP4808785B2 (https=)
CN (1) CN101389650B (https=)
AT (1) ATE519780T1 (https=)
DK (1) DK1969004T3 (https=)
ES (1) ES2371361T3 (https=)
PL (1) PL1969004T3 (https=)
PT (1) PT1969004E (https=)
WO (1) WO2007074133A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
WO2006051103A2 (en) * 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
EP1991576B1 (en) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
EP2024390B1 (en) * 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
MX2008014061A (es) * 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US9387176B2 (en) 2007-04-30 2016-07-12 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
US8710000B2 (en) * 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
JP5241849B2 (ja) * 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
WO2009112583A2 (en) 2008-03-14 2009-09-17 Novo Nordisk A/S Protease-stabilized insulin analogues
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US10842951B2 (en) 2010-01-12 2020-11-24 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US9180261B2 (en) 2010-01-12 2015-11-10 Dance Biopharm Inc. Preservative free insulin formulations and systems and methods for aerosolizing
US20130143803A1 (en) * 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN103167878A (zh) 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
JP2013545782A (ja) 2010-12-14 2013-12-26 ノヴォ ノルディスク アー／エス 長時間作用型インスリンと組み合わせた速効型インスリン
AU2012213432B2 (en) * 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
CA2872083A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
EP2919804B1 (fr) 2012-11-13 2018-01-31 Adocia Formulation à action rapide d'insuline comprenant un composé anionique substitué
JP6755175B2 (ja) * 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
AU2014333979B2 (en) 2013-10-07 2018-02-15 Novo Nordisk A/S Novel derivative of an insulin analogue
JP6723921B2 (ja) * 2014-01-09 2020-07-15 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
DK3006045T3 (en) 2014-10-07 2017-07-17 Cyprumed Gmbh Pharmaceutical formulations for oral administration of peptide or protein drugs
EP3261648B1 (en) * 2015-02-25 2023-12-06 Aerami Therapeutics, Inc. Liquid insulin formulations and methods relating thereto
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
JP7432361B2 (ja) * 2016-08-02 2024-02-16 江蘇恒瑞医薬股▲ふん▼有限公司 ヒトインスリンまたはそのアナログのアシル化誘導体
TWI700091B (zh) * 2016-12-16 2020-08-01 丹麥商諾佛 儂迪克股份有限公司 含胰島素醫藥組成物
CN111315766B (zh) * 2018-02-01 2023-05-12 江苏恒瑞医药股份有限公司 含人胰岛素类似物的酰化衍生物的药物组合物及其制备方法
KR20210016400A (ko) 2018-05-24 2021-02-15 지앙수 헨그루이 메디슨 컴퍼니 리미티드 재조합 인간 인슐린 또는 그 유사체의 전구체를 제조하는 방법
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
WO2021185304A1 (zh) * 2020-03-18 2021-09-23 东莞市东阳光生物药研发有限公司 制备长脂肪链二酸衍生物的方法及其应用
TW202229324A (zh) * 2020-11-27 2022-08-01 大陸商江蘇恒瑞醫藥股份有限公司 製備胰島素或其類似物的醯化衍生物的方法
JP2024522904A (ja) * 2021-06-25 2024-06-21 ガン アンド リー ファーマシューティカルズ カンパニー リミテッド アシル化インスリンを含む医薬組成物
US20230025595A1 (en) * 2021-07-13 2023-01-26 America Great Health, a California Corporation Formulation and Method of Preparing Divalent Cation Charged Insulin for Oral Administration
CN113896784B (zh) * 2021-10-18 2024-04-16 合肥天麦生物科技发展有限公司 一种胰岛素结晶的制备方法及其产品

Family Cites Families (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1212679B (de) 1957-08-03 1966-03-17 Novo Terapeutisk Labor As Verfahren zur Herstellung von Insulinloesungen
GB1042194A (en) 1962-04-30 1966-09-14 Olin Mathieson Insulin preparations
US3528960A (en) * 1968-10-07 1970-09-15 Lilly Co Eli N-carboxyaroyl insulins
US3907676A (en) 1970-07-28 1975-09-23 Novo Terapeutisk Labor As Process for purifying insulin
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1492997A (en) 1976-07-21 1977-11-23 Nat Res Dev Insulin derivatives
JPS5767548A (en) 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
FI78616C (fi) * 1982-02-05 1989-09-11 Novo Industri As Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt.
US4876322A (en) 1984-08-10 1989-10-24 Siemens Aktiengesselschaft Irradiation cross-linkable thermostable polymer system, for microelectronic applications
EP0174493B1 (de) 1984-08-17 1988-05-25 Bayer Ag Thermoplastische Formmassen mit flammwidrigen Eigenschaften
DE3433367A1 (de) 1984-09-12 1986-03-20 Robert Bosch Gmbh, 7000 Stuttgart Einrichtung zur steuerung der energiezufuhr zu einer heissen stelle
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPS61226115A (ja) 1985-03-30 1986-10-08 Mitsubishi Metal Corp 線条体押し出し機
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
US4764592A (en) 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
JPH01254699A (ja) 1988-04-05 1989-10-11 Kodama Kk インスリン誘導体及びその用途
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
KR910700262A (ko) 1988-12-23 1991-03-14 안네 제케르 사람 인슐린 유사체
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
IT1240314B (it) 1989-09-28 1993-12-07 Immunobiology Research Institutes, Inc. Formulazioni acquose stabilizzate di piccoli peptidi.
JP3122128B2 (ja) * 1989-12-21 2001-01-09 ノボ ノルディスク アクティーゼルスカブ ペプチド製剤
DK45590D0 (https=) 1990-02-21 1990-02-21 Novo Nordisk As
DK175491D0 (da) 1991-10-18 1991-10-18 Novo Nordisk As Apparat
DK0618807T3 (da) 1991-12-20 2003-03-03 Novo Nordisk As Stabiliseret farmaceutisk formulering omfattende human væksthormon og histidin
US5672581A (en) 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
US6869930B1 (en) * 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US6011007A (en) * 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
AU3562195A (en) 1994-10-04 1996-04-26 Novo Nordisk A/S Preparations containing aspb28 human insulin and nicotinamide
US5693609A (en) 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US5646242A (en) 1994-11-17 1997-07-08 Eli Lilly And Company Selective acylation of epsilon-amino groups
US5830999A (en) * 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
PL183698B1 (pl) 1995-03-17 2002-06-28 Novo Nordisk As Pochodna insuliny, kompozycja farmaceutyczna i zastosowanie pochodnej insuliny
US6251856B1 (en) * 1995-03-17 2001-06-26 Novo Nordisk A/S Insulin derivatives
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6451970B1 (en) * 1996-02-21 2002-09-17 Novo Nordisk A/S Peptide derivatives
US5866538A (en) * 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5905140A (en) * 1996-07-11 1999-05-18 Novo Nordisk A/S, Novo Alle Selective acylation method
ATE278711T1 (de) 1996-07-11 2004-10-15 Novo Nordisk As Verfahren zur selektiven acetylierung
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
DK0821006T3 (da) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
IL119029A0 (en) 1996-08-07 1996-11-14 Yeda Res & Dev Long-acting drugs and pharamaceutical compositions comprising them
US5898067A (en) * 1997-02-07 1999-04-27 Novo Nordisk A/S Crystallization of proteins
EP0969860B1 (en) 1997-03-20 2002-07-17 Novo Nordisk A/S Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer
ATE219942T1 (de) 1997-03-20 2002-07-15 Novo Nordisk As Therapeutische pulverformulierung zur pulmonaren anwendung, welche kristallines insulin enthält
US7097845B2 (en) 1997-04-23 2006-08-29 Jacob Sten Petersen Combinations of antigen and mucosal binding component for inducing specific immunological tolerance
DK1283051T3 (da) 1997-06-13 2006-10-16 Lilly Co Eli Stabile insulinformuleringer
ZA984697B (en) 1997-06-13 1999-12-01 Lilly Co Eli Stable insulin formulations.
US20020155994A1 (en) * 1997-10-24 2002-10-24 Svend Havelund Aggregates of human insulin derivatives
EA200000453A1 (ru) 1997-10-24 2000-10-30 Эли Лилли Энд Компани Композиции нерастворимого инсулина
CN1240718C (zh) 1997-10-24 2006-02-08 诺沃挪第克公司 人胰岛素衍生物的聚集体
US6451762B1 (en) * 1997-10-24 2002-09-17 Novo Nordisk A/S Aggregates of human insulin derivatives
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
CA2309955A1 (en) 1997-11-12 1999-05-20 Alza Corporation Method for decreasing self-association of polypeptides
US6531448B1 (en) * 1997-12-23 2003-03-11 Eli Lilly And Company Insoluble compositions for controlling blood glucose
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
ES2177323T3 (es) * 1998-10-16 2002-12-01 Novo Nordisk As Preparaciones de insulina concentradas estables para la administracionpor via pulmonar.
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
ES2180511T3 (es) * 1999-01-26 2003-02-16 Lilly Co Eli Formulaciones monodispersas de analogos de insulina acilados hexamericos.
EP2921180B1 (en) 1999-02-22 2019-08-14 University of Connecticut Albumin-free factor VIII formulations
AU4450700A (en) 1999-04-27 2000-11-10 Eli Lilly And Company Insulin crystals for pulmonary administration
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US6652886B2 (en) * 2001-02-16 2003-11-25 Expression Genetics Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
JP4624600B2 (ja) * 2001-06-08 2011-02-02 トヨタ自動車株式会社 焼結合金、その製造方法およびバルブシート
AU2002316811A1 (en) 2001-06-28 2003-03-03 Novo Nordisk A/S Stable formulation of modified glp-1
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
US20030068361A1 (en) 2001-10-09 2003-04-10 Rimona Margalit Liposome-encapsulated insulin formulations
PL374949A1 (en) 2001-12-20 2005-11-14 Eli Lilly And Company Insulin molecule having protracted time action
US8003605B2 (en) * 2002-03-13 2011-08-23 Novo Nordisk A/S Minimising body weight gain in insulin treatment
EP1506003A1 (en) 2002-05-07 2005-02-16 Novo Nordisk A/S Soluble formulations comprising insulin aspart and insulin detemir
JP5599543B2 (ja) * 2002-05-07 2014-10-01 ノヴォ ノルディスク アー／エス 単量体インスリン及びアシル化インスリンを含む可溶性製剤
US20050232899A1 (en) 2002-05-31 2005-10-20 Aradigm Corporation Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b
US20040002451A1 (en) 2002-06-20 2004-01-01 Bruce Kerwin Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing
KR100615389B1 (ko) 2002-08-23 2006-08-25 (주)헬릭서 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품
EP1562626B1 (en) 2002-10-29 2007-11-28 ALZA Corporation Stabilized, solid-state polypeptide particles
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes
CN101822834A (zh) 2003-02-07 2010-09-08 味之素株式会社 糖尿病治疗药
CA2787820A1 (en) 2003-02-19 2004-09-02 Novartis Ag Glycoprotein antigen sima135 expressed in metastatic human tumor cells
EA200501422A1 (ru) * 2003-03-04 2006-04-28 Дзе Текнолоджи Девелопмент Компани Лтд. Длительнодействующая инъецируемая композиция инсулина и способы её изготовления и применения
WO2004112828A1 (en) 2003-06-25 2004-12-29 Novo Nordisk Health Care Ag Liquid composition of factor vii polypeptides
US20050054818A1 (en) 2003-07-02 2005-03-10 Brader Mark Laurence Crystalline compositions for controlling blood glucose
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
MXPA06001283A (es) 2003-08-05 2006-04-11 Novo Nordisk As Derivados de insulina novedosos.
SI2107069T1 (sl) 2003-08-05 2013-04-30 Novo Nordisk A/S Novi inzulinski derivati
ES2574581T3 (es) 2003-08-14 2016-06-20 Novo Nordisk Health Care Ag Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII
JP5518282B2 (ja) 2003-09-01 2014-06-11 ノヴォ ノルディスク アー／エス 安定なペプチドの製剤
ES2229931B1 (es) 2003-10-03 2006-01-16 Grifols, S.A. Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos.
EP1687428A1 (en) * 2003-11-14 2006-08-09 Novo Nordisk A/S Processes for making acylated insulin
US8338374B2 (en) 2003-12-23 2012-12-25 Pharmacia Corporation Stable growth hormone liquid formulation
DE602005014962D1 (de) 2004-03-12 2009-07-30 Biodel Inc Insulinzusammensetzungen mit verbesserter wirkstoffabsorption
EP1750750B1 (en) 2004-06-01 2012-02-01 Ares Trading S.A. Method of stabilizing proteins
WO2006008238A1 (en) 2004-07-16 2006-01-26 Novo Nordisk A/S Method for selective acylation
DE602005022895D1 (de) 2004-08-12 2010-09-23 Schering Corp Stabile pegylierte interferon-formulierung
PT1778723E (pt) 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
WO2006051103A2 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of peptides
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
CA2593112A1 (en) 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
EP1846447B1 (en) 2005-02-02 2013-08-21 Novo Nordisk A/S Insulin derivatives
WO2006082204A1 (en) 2005-02-02 2006-08-10 Novo Nordisk A/S Insulin derivatives
WO2007041481A1 (en) 2005-09-29 2007-04-12 Biodel, Inc. Rapid acting and prolonged acting insulin preparations
JP2009512709A (ja) 2005-10-20 2009-03-26 エムディーアールエヌエー，インコーポレイテッド 速効型インスリンの経鼻投与
JP4808785B2 (ja) 2005-12-28 2011-11-02 ノボ・ノルデイスク・エー／エス インスリン組成物および組成物の製造方法
EP1991576B1 (en) * 2006-02-27 2010-09-29 Novo Nordisk A/S Insulin derivatives
CN101454019A (zh) 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
WO2007121256A2 (en) 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
EP2024390B1 (en) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulin derivative
MX2008014061A (es) 2006-05-09 2008-11-14 Novo Nordisk As Derivado de insulina.
WO2007135117A2 (en) 2006-05-24 2007-11-29 Novo Nordisk A/S Soluble, stable insulin-containing formulations
DK2074141T3 (en) 2006-09-22 2016-11-28 Novo Nordisk As The protease resistant insulin analogues.
US9034818B2 (en) * 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
EP2178910B1 (en) 2007-08-15 2014-10-08 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
US8710000B2 (en) 2007-11-08 2014-04-29 Novo Nordisk A/S Insulin derivative
JP5241849B2 (ja) 2007-11-16 2013-07-17 ノボ・ノルデイスク・エー／エス インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
CN102037008B (zh) 2008-03-18 2016-08-31 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、酰化胰岛素类似物
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
AU2009309623B9 (en) 2008-10-30 2014-10-02 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US20130143803A1 (en) 2010-05-10 2013-06-06 Novo Nordisk A/S Process for the Preparation of Insulin-Zinc Complexes
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
CN103167878A (zh) 2010-10-27 2013-06-19 诺沃—诺迪斯克有限公司 采用在不同注射时间间隔给予的胰岛素注射剂治疗糖尿病
AU2012213432B2 (en) 2011-02-01 2016-10-13 Novo Nordisk A/S Purification of insulin
AU2012223282B2 (en) 2011-03-01 2017-02-02 Nutrition 21, Llc Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
US10293109B2 (en) 2011-09-13 2019-05-21 Novo Nordisk A/S Adaptive system for optimizing a drug dosage regimen over time
US9481721B2 (en) 2012-04-11 2016-11-01 Novo Nordisk A/S Insulin formulations
CA2872083A1 (en) 2012-05-01 2013-11-07 Novo Nordisk A/S Pharmaceutical composition
JP6755175B2 (ja) 2013-03-20 2020-09-16 ノヴォ ノルディスク アー／エス インスリン投薬レジメン
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
CN111032685A (zh) 2017-08-17 2020-04-17 诺沃挪第克公司 新型酰化胰岛素类似物及其用途

Also Published As

Publication number Publication date
ES2371361T3 (es) 2011-12-30
PT1969004E (pt) 2011-11-25
EP1969004A2 (en) 2008-09-17
JP2011006428A (ja) 2011-01-13
JP5026567B2 (ja) 2012-09-12
JP2011121963A (ja) 2011-06-23
WO2007074133A2 (en) 2007-07-05
PL1969004T3 (pl) 2012-01-31
US20090074882A1 (en) 2009-03-19
JP2009522231A (ja) 2009-06-11
WO2007074133A3 (en) 2007-10-11
US20140328943A1 (en) 2014-11-06
EP1969004B1 (en) 2011-08-10
EP2505593A1 (en) 2012-10-03
DK1969004T3 (da) 2011-11-28
CN101389650B (zh) 2012-10-10
US11167035B2 (en) 2021-11-09
JP4808785B2 (ja) 2011-11-02
CN101389650A (zh) 2009-03-18

Similar Documents

Publication Publication Date Title
ATE519780T1 (de) Ein acyliertes insulin und zink enthaltende zusammensetzungen und verfahren zur herstellung dieser zusammensetzungen
DE602007011171D1 (de) Zusammensetzung und Verfahren zur Herstellung von Steviolglykosiden
DE602006011791D1 (de) Kollagenpulver und auf kollagen basierende thermoplastische zusammensetzung zur herstellung von formkörpern
WO2007081978A3 (en) Modulators of hepatocyte growth factor / c-met activity
ATE473224T1 (de) Verfahren zur herstellung von nebivolol
ATE538816T1 (de) Verfahren zur herstellung eines bioaktiven implantats
ATE430480T1 (de) Verfahren zur herstellung von nährmittelzusammensetzungen
DE602006009192D1 (de) Verfahren zur Herstellung von Dünnschichttransistoren mit Top-Gate-Geometrie
WO2008129358A8 (en) Oil producing microbes and methods of modification thereof
DE602005018981D1 (de) Verfahren zur Herstellung von L-Cystein, und L-Cystein-produzierender Mikroorganismus
ATE536165T1 (de) Dentalabdruckmaterial mit rheologischen modifikatoren und verfahren zu seiner herstellung
DE602006011590D1 (de) Verfahren zur herstellung anallergischer probiotischer bakterienkulturen und entsprechende verwendung
EP4430018A4 (en) BIOCARBON COMPOSITIONS WITH OPTIMIZED COMPOSITION PARAMETERS AND THEIR PRODUCTION PROCESSES
WO2004110376A3 (en) Ccr-2 antagonists for treatment of neuropathic pain
IL144830A0 (en) Ribosomes structure and protein synthesis inhibitors
DE102005001078A8 (de) Glaspulver, insbesondere biologisch aktives Glaspulver und Verfahren zur Herstellung von Glaspulver, insbesondere biologisch aktivem Glaspulver
ATE496967T1 (de) Verfahren zur herstellung von einer aromatischen polycarbonat-harzzusammensetzung und geformter artikel daraus
ZA200605593B (en) Process for the production of compositions containing ribonucleotides and their use as flavouring agents
DE602005001688D1 (de) Aufbereitung von Aldesleukin zur pharmazeutischen Verwendung
DE602006006009D1 (de) Methode zur Herstellung von Acrylsäure
DE602006014660D1 (de) Verfahren zur herstellung von avocadopulver
DE60127675D1 (de) Neuartige insulin synthase und verfahren zur herstellung von insulin durch anwendung derselben
ATE435864T1 (de) Substituierte 5,6,7,8-tetrahydro-imidazoä1 ,2- aüpyridin-2-ylamin-verbindungen und deren verwendung zur herstellung von arzneimitteln
ATE448316T1 (de) Verfahren zur herstellung einer zusammensetzung auf 4-hydroxyprolin-basis sowie verwendungen davon auf landwirtschaftlichem gebiet
DE602006016199D1 (de) Nadellager mit einem Käfig und Verfahren zur Herstellung des Käfigs

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1969004

Country of ref document: EP